Irritable Bowel Syndrome News

Takeda Pharmaceuticals and Enterome Bioscience SA today announced they will collaborate on research and development of new potential therapies aimed at microbiome targets believed to be involved in GI disorders like inflammatory bowel disease and irritable bowel syndrome, according to a press release.

New research confirms previous findings that stress and infectious gastroenteritis are associated with new-onset irritable bowel syndrome among members of the U.S. military.

Psychological therapies were found to provide short- and long-term reductions in gastrointestinal symptoms in adults with irritable bowel syndrome, according to the results of a recent meta-analysis.

A majority of individuals with irritable bowel syndrome have low concentrations of serum 25-hydroxyvitamin D levels, which are positively associated with quality of life, according to recent study results.

The AGA has released results from its IBS in America survey, which shows patients have a significant daily burden affecting them physically, emotionally and socially, and highlights the need for improved communication between patients and health care providers, according to a press release.

Allergan today announced the availability of Viberzi, its first-in-class, twice-daily oral treatment for adults with diarrhea-predominant irritable bowel syndrome in the U.S.

Linaclotide improved symptoms and increased complete spontaneous bowel movements in adults with constipation-predominant irritable bowel syndrome in a phase 3 Japanese clinical trial, the manufacturer announced.

The U.S. Patent and Trademark Office has issued a patent to Synthetic Biologics covering the active agent in SYN-010, the company’s novel microbiome-based drug candidate for the treatment of constipation-predominant irritable bowel syndrome, according to a press release.

Ramosetron, a 5-hydroxytryptamine-3 antagonist used in Japan, Korea and Thailand to treat male patients with diarrhea-predominant irritable bowel syndrome, was found to reduce symptoms, increase stool consistency and improve quality of life in women in a recent phase 3 clinical trial.

SAN ANTONIO — A high prevalence of food sensitization and positive history of lower gastrointestinal symptoms with certain foods indicated a significant role for food allergen sensitization in the pathogenesis of atopic irritable bowel syndrome, according to study results presented at the 2015 American College of Allergy, Asthma and Immunology Annual Scientific Meeting.